You neglect the USD$ milestone millions that will come before the first royalty payment but yes it will take 2 years for Ipix to receive USD$50 million from Alfasigma for this small rectum use of Brilacidin.
But I do not think Ipix will need to pay a Brilacidin Phase 3 trial within the next 2 years with only their own money. I think their new partners will pay for most. I think the next Phase 3 that Ipix pays alone is maybe Kevetrin. That will cost USD$150 million or more but is a super good investment. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448420/ https://clinicaltrials.gov/ct2/show/NCT03042702
News 
Market Data 
Discover 
